Night-Time Apomorphine Infusion: Who Are the Best Candidates?
Parkinson's disease
apomorphine
insomnia
motor fluctuations
sleep
sleepiness
treatment
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
14
02
2023
revised:
28
04
2023
accepted:
08
05
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
We recently demonstrated in a randomized controlled trial (APOMORPHEE, NCT02940912) that night-time only subcutaneous apomorphine infusion improves sleep disturbances and insomnia in patients with advanced Parkinson's disease and moderate to severe insomnia. To identify the best candidates for receiving night-time only subcutaneous apomorphine infusion in routine care. In this post-hoc analysis of APOMORPHEE, we compared the characteristics of patients according to whether they chose to continue night-time only subcutaneous apomorphine infusion at the end of the study period or not. Half of the patients (22/42) chose to continue the treatment. Off duration (day or night), painful Off dystonia, and insomnia severity at baseline were associated with night-time only apomorphine continuation. Multivariate analysis retained only Off duration as an independent predictor of continuation. The best candidates for night-time only apomorphine are patients with severe and prolonged Off periods (day or night) and severe insomnia.
Sections du résumé
Background
UNASSIGNED
We recently demonstrated in a randomized controlled trial (APOMORPHEE, NCT02940912) that night-time only subcutaneous apomorphine infusion improves sleep disturbances and insomnia in patients with advanced Parkinson's disease and moderate to severe insomnia.
Objectives
UNASSIGNED
To identify the best candidates for receiving night-time only subcutaneous apomorphine infusion in routine care.
Methods
UNASSIGNED
In this post-hoc analysis of APOMORPHEE, we compared the characteristics of patients according to whether they chose to continue night-time only subcutaneous apomorphine infusion at the end of the study period or not.
Results
UNASSIGNED
Half of the patients (22/42) chose to continue the treatment. Off duration (day or night), painful Off dystonia, and insomnia severity at baseline were associated with night-time only apomorphine continuation. Multivariate analysis retained only Off duration as an independent predictor of continuation.
Conclusions
UNASSIGNED
The best candidates for night-time only apomorphine are patients with severe and prolonged Off periods (day or night) and severe insomnia.
Identifiants
pubmed: 37635769
doi: 10.1002/mdc3.13799
pii: MDC313799
pmc: PMC10450238
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1192-1197Informations de copyright
© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Clin Drug Investig. 2018 Apr;38(4):287-312
pubmed: 29327219
Clin Park Relat Disord. 2021 Dec 24;6:100129
pubmed: 35005605
Parkinsonism Relat Disord. 2013 Dec;19(12):1073-8
pubmed: 24051336
Parkinsonism Relat Disord. 2016 Dec;33 Suppl 1:S13-S21
pubmed: 27979722
Mov Disord. 2019 Mar;34(3):353-365
pubmed: 30719763
J Neurol. 2017 May;264(5):946-954
pubmed: 28364292
NPJ Parkinsons Dis. 2021 Jun 11;7(1):50
pubmed: 34117268
J Neurol Neurosurg Psychiatry. 2007 May;78(5):476-9
pubmed: 17098844
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804
pubmed: 12388666
Mov Disord. 2015 Apr;30(4):510-6
pubmed: 25382161
Mov Disord. 2011 Feb 15;26(3):399-406
pubmed: 21264941
Parkinsonism Relat Disord. 2015 Sep;21(9):1023-30
pubmed: 26189414
Science. 2013 Oct 18;342(6156):373-7
pubmed: 24136970
Acta Neurol Scand. 1999 Sep;100(3):163-7
pubmed: 10478579
Mov Disord. 1993 Apr;8(2):165-70
pubmed: 8474483
Parkinsonism Relat Disord. 2016 Feb;23:17-22
pubmed: 26709292
Mov Disord. 2008 Jun 15;23(8):1130-6
pubmed: 18442107
Int J Mol Sci. 2022 Oct 26;23(21):
pubmed: 36361716
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S127-33
pubmed: 26453387
Mov Disord. 2006 May;21(5):727-8
pubmed: 16547919
Mov Disord. 2022 Jul;37(7):1360-1374
pubmed: 35791767
Lancet Neurol. 2022 May;21(5):428-437
pubmed: 35429481
J Parkinsons Dis. 2016 Oct 19;6(4):787-792
pubmed: 27662329
J Parkinsons Dis. 2011;1(2):197-203
pubmed: 23934921
Parkinsonism Relat Disord. 2021 Feb;83:79-85
pubmed: 33486139
Lancet Neurol. 2018 Sep;17(9):749-759
pubmed: 30055903